A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2015
Price : $35 *
At a glance
- Drugs PF 6412562 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Feb 2014 Planned initiation date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.